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Hematopoietic stem cell transplantation (HSCT)
may be considered as an inappropriate technology in
a developing country because of the high cost of
the procedure for an individual patient [1]. To make
this modality available to a larger population as
a life-saving treatment, innovations and modifications
are required to reduce the cost without compromising
the outcomes. This article describes our attempts to
develop a cost-effective HSCT program in India [2].
Transplant Unit
The HSCT program at Christian Medical College
(CMC), Vellore, was started in 1986, and up to De-
cember 2007, approximately 700 transplants have
been performed, the majority from matched family
donors.
In January 2008 a new transplant unit with 10 pos-
itive-pressure HEPA-filtered rooms for allogeneic
transplants and 8 rooms for autologous transplants
with all support facilities and a floor area of 1500
square meters was completed at a total cost of
$750,000. Because infection control is of utmost im-
portance in developing countries, surveillance micro-
biology for air quality is done once a month with
blood agar plates for bacterial counts and Sabouraud’s
dextrose agar for fungi. Water for the patient’s toilet
needs and for cleaning the unit is UV sterilized and ter-
minally filtered with a 0.2-micron shower head filter
(Pall AQL3).
Unrelated Donor Registry in India
Thematched unrelated donor transplant field is far
lagging behind because of a lack of a formal national-
ized unrelated donor registry program in India. TheHematology Department, Christian Medical College,
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Conditioning Regimens
Currently, only well-tried out regimens are being
used because of a higher cost of new drugs. Reduced-
intensity conditioning (RIC) regimens are increasingly
being preferred for acute leukemias and aplastic ane-
mia (AA), in view of decreased toxicity and less sup-
portive care needs.
The following conditioning regimes are in use:
1. Thalassemia: busulfan (Bu), cyclophosphamide
(Cy) 6 antithymocyte globulin (ATG);
2. Acute myelogenous leukemia (AML): Bu 16 1 Cy
120 was the standard regimen; more recently,
RIC with fludarabine (Fl) and melphalan (Mel)
has been preferred. For relapsed/refractory AML,
if there is an HLA matched sibling donor available,
it may be more cost effective to combine reinduc-
tion with FLAG-Ida followed by allogeneic stem
cell rescue (avoiding the cost and toxicity of prepar-
ative regimen), but this approach is being evaluated
in a larger number of patients [3,4];
3. Acute lymphoblastic leukemia (ALL): standard
fractionated total body irradiation (TBI) (1200
cGy) and Cy 120 mg/kg;
4. Severe AA (SAA): fludarabine (Flu; 180 mg/m2) and
Cy (120 mg/kg) is the preferred regimen, and ATG
(ATGAM, 40 mg/kg) is added only if the patient
does not harbor any major infection at the time
of transplant and has adequate financial resources
[5].
In the developing world, the choice of condition-
ing regimen is critical, because rejection, treatment-
related morbidity, and graft-versus-host disease
(GVHD) will significantly increase the cost of the pro-
cedure.
Bone Marrow Harvest
Bone marrow is still the preferred graft source for
thalassemia at our center, because peripheral blood
stem cells (PBSCs) carry a higher risk of chronic95
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harvest is done using sternal aspiration needles, and
this is associated with much less postharvest pain.
The marrow is put into a collection system fabricated
in-house with a 1-liter sterile bag docked to a 170-m fil-
ter. For major ABO mismatched transplants, red cell
depletion is done using hydroxyethyl starch and grav-
ity sedimentation. For leukemia, PBSCs are collected
using a Cobe Spectra after administration of granulo-
cyte colony-stimulating factor (G-CSF) to the donor.
GVHD Prophylaxis
Short-course methotrexate (MTX) and cyclospor-
ine (CsA) are still the main agents used, but we are
exploring other regimes without MTX, particularly
where earlier engraftment will significantly reduce
transplant-related morbidity, for example, patients
with SAA who have infection at the time of transplant,
and in patients with Lucarelli Class III thalassemia
where sinusoidal obstruction syndrome (SOS) is a ma-
jor problem [6]. GVHD is treated with steroids and
additional agents as required. Monoclonal antibodies
(mAbs) are used only in those situations where there
are no financial constraints. We are also studying the
use of third-party mesenchymal cells (MSC) in steroid
refractory GVHD. The MSC are produced in-house
from third-party bone marrow in a GMP facility and
are released only after meeting stringent criteria.
This is a Department of Biotechnology, Government
of India funded trial, and hence, accurate cost is not
available at present.
Blood Products
All cellular blood products are irradiated with
a blood irradiator indigenously manufactured by the
Atomic Energy Commission of India at one-third the
cost of irradiators available in the West. Packed red
cell transfusions are given to maintain Hb .9 g%
and platelet transfusion to maintain platelet counts
around 20,000/cumm. We insist on 1 or 2 relative
donors being available in the peritransplant period to
provide single-donor platelets.
Leukodepletion filters are not routinely used
because this will increase the total transplant cost by
10% to 15%, even though most patients and donors
are cytomegalovirus (CMV) IgG positive.
Incidence of hepatitis in pretransfused thalassemia
patients has been analyzed. Five of 243 (2.05%) pa-
tients were HBs Ag positive and 31 of 243 (12.75%)
were HCV Ab positive prior to HSCT. Lamuvidine
is given to HBs Ag-positive patients pre-transplant,
and booster doses of hepatitis B vaccination are given
to the patient and donor if the HBSAb titer is less than
100 IU. The outcomes of HSCT for HBs Ag-positive
patients has not been adversely affected using this
strategy. The hepatitis C positivity also does not affectthe HSCT outcomes provided the liver function tests
are within normal limits. PEG interferon and Ribavar-
ine is used posttransplant if the patient remains HCV
postitive once the serum ferritin levels return to nor-
mal, to prevent viral replication. Although this adds
to the cost of HSCT, there is no choice if the patient
remains HCV positive.
Chimerism
We have developed an algorithm of STR/VNTR
markers for evaluation of chimerism posttransplant,
with quantification being done using gene scan. The
cost of this indigenous chimerism analysis is US$ 50.
Testing is done at day 130 and only if there is mixed
chimerism testing is repeated at a frequency depending
on the clinical situation [7].
Infection Management
No prophylactic antimicrobials are administered
pretransplant. Acyclovir is started on day 11 to pre-
vent herpes simplex, but fluconazole is not given pro-
phylactically. Gram-negative sepsis is more frequent
than Gram-positive infections and recently pan-resis-
tant nosocomial infection is becoming a problem. If fe-
ver persists .72 hours, conventional amphotericin
desoxycholate is administered as a 4-hour infusion. If
there is CT evidence of fungal infection then Voricona-
zole or caspofungin is added. A generic liposomal am-
photericin preparation (Fungizome), which is one-fifth
the cost of Ambisome is used when there is infusional
toxicity with amphotericin desoxycholate [8].
All patients transplanted and their donors so far
have been CMV IgG positive. Posttransplant CMV-
polymerase chain reaction (PCR) is done on day 130,
and if negative, repeated only if there is clinical suspi-
cion of CMV or if the patient has developed GVHD
requiring immunosuppression. Pre-emptive treatment
with ganciclovir is started if a negative CMV-PCR
becomes positive or there is a rising titer [9].
Intravenous immunoglobulin at a dose of 400mg/kg
every 4 weeks is given as prophylaxis in a few patients
where there are no resource constraints. Once engraft-
ment has occurred, cotrimoxazole and oral penicillin
are started and continued for 1 year posttransplant.
Using the above-mentioned strategy for the
CMV monitoring and without the use of leukodeple-
tion filters for transfusions, the incidence of CMV
reactivation is 38.8% and CMV disease has been docu-
mented in 23.1% patients; the majority of these
patients were on increased immunosuppression for
GVHD. Therefore, more active CMV monitoring is
currently being advocated for patients with GVHD.
No prophylaxis is given for tuberculosis or malaria
because there would be too many drug interactions in
the posttransplant period, and these infections can be
diagnosed and treated as and when necessary [10].
Table 1. Allogeneic transplants: October 1986 to December
2007
Diagnosis N Overall Survival%
Thalassemia major 242 71
Chronic myeloid leukemia 99 44
Acute myeloid leukemia 132 36
Aplastic anemia 102 61
Acute lymphoblastic leukemia 44 30
MDS 32 41
Multiple myeloma 3 100
PNH 6 67
Myelofibrosis 5 60
Fanconi anemia 8 50
MDS indicates myelodysplastic syndrome; PNH, paroxysmal nocturnal
hemoglobinuria.
Table 2. Outcome of Allogeneic BMT for Thalassemia
1986-2007
Class Number
Survival
(%)
Event-Free
Survival (%)
Rejection
(%)
Mortality
(%)
All patients 218 159 (72.9) 142 (64.7) 32 (14.1) 59 (27.1)
Class I 15 11 (73.3) 11(73.3) 0 4 (26.7)
Class II 78 66 (84.6) 63 (80.8) 8 (10.3) 12 (15.4)
Class III 125 82 (65.6) 67 (53.6) 24 (19.4) 43 (34.4)
BMT indicates bone marrow transplantation.
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All food given to the patient is prepared by the rel-
atives who pressure cook the food in a pantry adjacent
to the transplant unit; this keeps the relatives busy, de-
creases the cost to the hospital, and the patient gets the
type of food that he is used to having at home. Total
parenteral nutrition (TPN) is started when the oral in-
take is poor, using commercial products at a cost of $30
per day for 2000 calories. Lipid is used only if long-
term nutritional support is required for patients with
gut GVHD. An ELD 96 (Pall) filter is used on the
TPN line and this is changed every fourth day.
Most families rent an apartment for $30 per month
where they cook their own food and stay until the pa-
tient is discharged and ready to go home. Patients gen-
erally stay in-house until they are totally free of
complications, because the supportive care available
in their home town may not be adequate. Therefore,
average length of stay cannot be used as a variable
for comparisons with other transplant programs.Results of HSCT
In the transplant program started in 1986 and up to
December 2007, a total of 718 allogeneic transplants
have been performed in 683 patients. Table 1 gives
the indications for transplant and the outcomes. The
median age of patients was 16 years (range: 5 months
to 64 years) with 67.8% of the patients being males.
The age distribution is shown in Figure 1, with halfFigure 1. Age distribution of patients transplanted 1986-2007.of the transplants being done in children. Table 2 gives
the results of bone marrow transplantation (BMT) for
thalassemia, and the outcome in Class II is similar to
that reported from Pesaro, India [11]. RIC with Flu
and Mel for AML is associated with much lower
treatment-related mortality (TRM), and, therefore,
a lower cost, and short-term overall survival (OS)
appears to be better than ablative conditioning with
Bu and Cy [3]. For SAA, conditioning with Flu and
Cy has reduced rejection with better survival: we do
not wait for resolution of fevers before starting condi-
tioning in severely neutropenic patients.
Cost
Figure 2 shows the cost distribution for BMT at
CMC, Vellore. The total cost of HSCT ranges from
$20,000 to $75,000, depending upon the type of donor
and complications representative cost of BMT in pa-
tients with thalassemia, leukemia and aplastic anemia
depending on the presence or absence of complica-
tions is shown in Table 3.
The first matched unrelated SCT for a 45-year-
old male with AML in the second complete remission
(CR2) was recently done at this center, with stem cells
procured through the National Marrow Donor
Program (NMDP) from a donor in Florida: the cost
of high-resolution typing of patient and donors, col-
lection of stem cells, and carriage to India was US$
40,000, and the transplant cost in India was only
US$ 30,000. Therefore, it is logical to develop
a matched unrelated transplant program locally,
with the graft sourced from anywhere in the world
and patients traveling here for HSCT at a much
reduced cost.Figure 2. Alogeneic BMT—cost distribution 2007.
Table 3. Representative Cost of Transplant in Individual
Patients
Diagnosis UPN Age BSAm2
Hospital
Stay
(Days)
Cost of
Transplant
in US$
Aplastic anemia uncomplicated 458 29 1.67 28 14,000
Aplastic anemia complicated 701 46 1.59 145 72,000
Thalassemia uncomplicated 731 4 0.62 46 14,000
Thalassemia complicated 707 10 1.0 51 22,000
Acute leukemia uncomplicated 697 38 1.5 31 11,000
Acute leukemia complicated 672 17 1.64 146 57,000
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effective allogeneic stem cell transplant program in
the developing world that will provide the patient
a life-saving treatment at an affordable cost in his
own country. Development of indigenous technology,
cost-effective drug intervention, and monitoring strat-
egies and continuous analysis of outcomes are impor-
tant factors in developing such a program.ACKNOWLEDGMENTS
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